IHT Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

IHT Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-667	Closed	-$38K	–	947
2021 Q1	$38K	Sell	667 -200	-23%	-$15.1K	﹤0.01%	826
2020 Q4	$59K	Hold	867	–	–	﹤0.01%	731
2020 Q3	$220K	Hold	867	–	–	0.02%	582
2020 Q2	$146K	Hold	867	–	–	0.02%	542
2020 Q1	$60K	Hold	867	–	–	0.01%	527
2019 Q4	$56K	Hold	867	–	–	0.01%	610
2019 Q3	$51K	Sell	867 -286	-25%	-$16.9K	0.01%	599
2019 Q2	$68K	Hold	1,153	–	–	0.01%	528
2019 Q1	$75K	Buy	1,153 +286	+33%	+$16.3K	0.01%	498
2018 Q4	$46K	Buy	867 +134	+18%	+$6.6K	0.01%	463
2018 Q3	$42K	Hold	733	–	–	0.01%	421
2018 Q2	$43K	Buy	733 +133	+22%	+$7.83K	0.01%	404
2018 Q1	$29K	Hold	600	–	–	0.01%	851
2017 Q4	$31K	Buy	+600	New	+$35.9K	0.01%	846

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IHT Wealth Management's BCLI Position: Q2 2021 in Review

IHT Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 667 shares — an estimated $38K sold.

IHT Wealth Management first reported a position in BCLI in Q4 2017 and held it in 14 quarters. The position peaked at $220K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

IHT Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
IHT Wealth Management sold 667 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $38K.
IHT Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2017 and held it in 14 quarters.
IHT Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $220K in Q3 2020.
57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on IHT Wealth Management's 13F filing for Q2 2021, filed 16 Aug 2021.